Biotech Archives - Page 109 of 795

3 minute read

MangoRx Accepting Pre Orders For Its “PRIME”, by MangoRx, Powered By Kyzatrex FDA Approved Oral Testosterone Replacement Therapy Product

February 5, 9:52 AM

The Dallas Based, Direct-to-Consumer Telemedicine Company to Offer 2 Months of Free ‘PRIME' by MangoRx, Powered by Kyzatrex®️ (a $498 value) for First 1,000 SubscribersDallas, Texas, Feb. 05, 2024 (GLOBE

MGRX

2 minute read

Ozempic Maker Strikes $11B Deal With Catalent As It Rushes To Meet Massive Weight-Loss Drug Demand

By Benzinga Neuro

February 5, 9:40 AM

This move comes on the heels of the company's recent collaborations to develop new treatment approaches for obesity management and chronic liver diseases.

CTLT

4 minute read

Tharimmune Announces Dosing Of First Patient In Phase 1 Clinical Trial Of TH104, Its Lead Candidate For Pruritus In Primary Biliary Cholangitis

By Benzinga Newsdesk

February 5, 9:35 AM

Phase 1 clinical trial dosing of first patient complete; primary objective to assess safety/tolerability and absolute bioavailability of TH104Phase 1 study expected to be completed in 1Q24 with topline readout in

THAR

3 minute read

Twist Bioscience Unveils Differentiated Ultra High-Throughput Library Preparation Solution At AGBT

By Benzinga Newsdesk

February 5, 9:24 AM

Early access of novel technology that enables preparation of thousands of samples at low cost through self-normalization, enhanced multiplexing, and streamlined workflowInnovative solution positioned to drive NGS

TWST

2 minute read

Celldex Announces Upcoming Presentation Of Barzolvolimab Phase 2 Results In Chronic Spontaneous Urticaria At AAAAI 2024

By Benzinga Newsdesk

February 5, 9:12 AM

Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that an abstract describing 12 week results from the Company's Phase 2 clinical trial of barzolvolimab in patients with moderate to severe chronic spontaneous

CLDX

1 minute read

Jasper Therapeutics Announces Preclinical Data Presentations At American Academy of Allergy, Asthma, and Immunology Annual Meeting

By Benzinga Newsdesk

February 5, 9:11 AM

etails of the presentations are as follows:Abstract Title: Briquilimab, An Anti-CD117 Antibody, Prevents Passive Systemic Anaphylaxis in Mice Expressing Chimeric Human and Mouse CD117 Through Mast Cell

JSPR

2 minute read

Vaxart Announces Publication In Vaccines Of Non-Human Primate Preclinical Data Demonstrating Its Next-Generation Vaccine Candidates Elicit Mucosal And Systemic Immunogenicity And Reduce Viral Shedding After SARS-CoV-2 Challenge

By Benzinga Newsdesk

February 5, 9:07 AM

— Data served as foundation for current vaccine candidate for planned Phase 2 research— Vaxart vaccine candidates elicited strong antigen-specific serum IgG and IgA with neutralizing activity

VXRT

2 minute read

Ocuphire Pharma Announces Presentation On APX3330 At The Annual Angiogenesis, Exudation, And Degeneration 2024 Conference

By Benzinga Newsdesk

February 5, 9:05 AM

Ocuphire Pharma, Inc. (NASDAQ:OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of retinal and refractive eye disorders,

OCUP

2 minute read

Clearmind Medicine Receives Patent Approval For Its Psychedelic Based Treatment Of Binge Behaviors In China

By Benzinga Newsdesk

February 5, 8:52 AM

Clearmind Medicine Inc. ((Nasdaq, CSE:CMND), (FSE: CWY) ("Clearmind" or the "company"), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health

CMND

1 minute read

4DMT Presents Interim Data From Randomized Phase 2 PRISM Clinical Trial Of Intravitreal 4D-150 Demonstrating Favorable Tolerability & Clinical Activity In Wet AMD

By Benzinga Newsdesk

February 4, 2:39 PM

51 wet AMD patients with severe disease activity (mean of 442 µm central subfield thickness & presence of retinal fluid) and high treatment burden (mean of 10 anti-VEGF injections in preceding 12 months) were

FDMT